Weight Loss Peptides
Are you familiar with names such as Ozempic, Wegovy, Zepbound, or Mounjaro? These modern medicines are often described as highly effective weight‑loss peptides. This is, of course, a significant simplification—but it also reflects the proven effectiveness of the active substances they contain.
The medications mentioned above are intended for the treatment of specific medical conditions (such as type 2 diabetes or obesity) and are relatively expensive. It is therefore not surprising that some people search online for therapeutic alternatives—significantly cheaper substances marketed as equivalents of well‑known drugs.
Reklama
Peptides that influence body weight reduction
In recent years, many modern peptide‑based medications have entered the market, intended for the treatment of type 2 diabetes, obesity, and overweight. Below you will find an overview of active substances used both in already approved medications and in compounds that are still under investigation—or have been discontinued.
Therapy effectiveness: It should be emphasized that achieving the desired therapeutic effect—namely weight loss—as well as long‑term maintenance of reduced body weight, depends on many factors. Peptide medications can support this goal, but sustainable lifestyle changes (regular physical activity and dietary modification) are also essential.
Weight loss peptides, more precisely peptide-based medications, can be described — put simply — as signaling substances. This means they activate, block, or regulate the body’s natural mechanisms in order to produce a specific therapeutic effect.
The dosing information provided on this website is for general informational purposes only and does not constitute medical advice or a basis for planning treatment. Its purpose is solely to help estimate the approximate duration and cost of therapy; individual consultation with a qualified physician is required in every case.
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
Tirzepatide
Tirzepatide is present in two approved medicines (Mounjaro and Zepbound), available as subcutaneous injection solutions (pens). In Europe, only Mounjaro is available. Initially approved for the treatment of type 2 diabetes, it is now also approved for obesity and overweight with comorbidities in selected countries.
Tirzepatide is a dual incretin receptor agonist (GIP and GLP‑1). As a result, it enhances glucose‑dependent insulin secretion, suppresses glucagon, slows gastric emptying, and strongly affects the brain’s satiety centers.
By acting on two receptors simultaneously, tirzepatide demonstrates greater clinical efficacy than semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), which act solely as GLP‑1 receptor agonists. The additional GIP activation translates into improved glycemic control and greater weight reduction compared to pure GLP‑1 agonists.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 2.5 mg (introduction dose for the first 4 weeks), 5 mg from weeks 5 to 8, 7.5 mg from weeks 9 to 12, 10 mg from weeks 13 to 16, 12.5 mg from weeks 17 to 20. Maximum 15 mg. |
|---|---|
| Frequency | 1× a week |
| Time of day | freely |
| Cycle on | continuous therapy — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | - |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
Semaglutide
Semaglutide is found in several approved medicines, including Ozempic, Wegovy, and Rybelsus. Ozempic and Wegovy are available as subcutaneous injections (pens), while Rybelsus is an oral tablet. In Europe, semaglutide is widely used to treat type 2 diabetes and—under the name Wegovy — obesity and overweight with comorbidities, in accordance with current regulatory approvals.
Semaglutide is a GLP‑1 receptor agonist, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and influencing appetite and satiety centers in the central nervous system. This mechanism leads to improved glycemic control and weight reduction. Unlike tirzepatide, semaglutide does not activate the GIP receptor, meaning its metabolic effects rely exclusively on the GLP‑1 pathway. Nevertheless, it remains one of the most extensively studied and widely used GLP‑1 agonists in clinical practice.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 0.25 mg from weeks 1 to 4, 0.5 mg from weeks 5 to 8, 1 mg from weeks 9 to 12, 1.7 mg from weeks 13 to 16, 2.4 mg from weeks 17 (for the treatment of obesity). |
|---|---|
| Frequency | 1× a week |
| Time of day | freely |
| Cycle on | continuous therapy — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | - |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
Liraglutide
Liraglutide is present in the approved medicines Victoza and Saxenda, available as subcutaneous injection solutions (pens). In Europe, liraglutide is used to treat type 2 diabetes (Victoza) and — under the brand name Saxenda — obesity and overweight with comorbidities, in line with regulatory approvals.
Liraglutide is a GLP‑1 receptor agonist that enhances glucose‑dependent insulin secretion, suppresses glucagon, slows gastric emptying, and affects appetite and satiety centers in the central nervous system. This leads to improved glycemic control and gradual weight reduction.
Unlike tirzepatide, liraglutide does not affect the GIP receptor, and compared to semaglutide, it has a shorter duration of action, requiring daily administration, while maintaining a well‑documented safety and efficacy profile.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 600 mcg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, 3 mg from week 5 (target dose). For diabetes – ma×. 1.8 mg |
|---|---|
| Frequency | every day |
| Time of day | freely |
| Cycle on | to achieve the desired therapeutic effect — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | - |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
Dulaglutide
Dulaglutide is present in the approved medicine Trulicity, available as a subcutaneous injection solution (pen). In Europe, dulaglutide is used to treat type 2 diabetes in adults (and adolescents in specific indications), both as monotherapy and in combination with other antidiabetic drugs. It is not approved for obesity treatment, although weight reduction may occur as a secondary effect.
Dulaglutide is a GLP‑1 receptor agonist, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and influencing appetite and satiety centers in the central nervous system. This results in improved glycemic control and a moderate effect on body weight. Compared with semaglutide, dulaglutide shows less potent weight‑loss effects, but its advantages include a stable and well‑documented safety profile and once‑weekly dosing, supporting high treatment adherence.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 0.75 mg (for the first 4 weeks), 1.5 mg (weeks 5-8), 3 mg (weeks 9-12), 4.5 mg (from week 13). Doses of 3 mg and 4.5 mg are optional as needed. |
|---|---|
| Frequency | every week |
| Time of day | freely |
| Cycle on | until a therapeutic effect is achieved — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | - |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
CagriSema
CagriSema is an experimental combination therapy currently in advanced clinical development, with no approved medicines available yet. It is being developed primarily for the treatment of obesity and overweight with comorbidities, as well as metabolic disorders, but remains investigational and not approved for clinical use.
CagriSema combines cagrilintide (an amylin analogue) with semaglutide, a GLP‑1 receptor agonist. Semaglutide enhances glucose‑dependent insulin secretion, suppresses glucagon, slows gastric emptying, and influences satiety centers, while cagrilintide acts via the amylin pathway, further enhancing satiety and reducing energy intake. The combination of these mechanisms provides a stronger and more multidirectional effect on appetite regulation and body weight than GLP‑1 monotherapy. However, the full efficacy and safety profile of CagriSema remains under evaluation in ongoing clinical trials.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 0.25 mg (first 4 weeks), 0.5 mg (weeks 5-8), 1 mg (weeks 9-12), 1.7 mg (weeks 13-16), maximum dose 2.4 mg from week 17 (optional). |
|---|---|
| Frequency | every week |
| Time of day | morning |
| Cycle on | Titrate every 4 weeks if well tolerated; reassess efficacy and tolerability every 12 weeks; do not escalate in case of significant adverse effects. — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | - |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
Mazdutide
Mazdutide is a next‑generation incretin‑based therapy currently in advanced clinical development and not approved in Europe or the United States. The compound was developed by Eli Lilly, with clinical and commercial development in China led by Innovent Biologics. In China, mazdutide has already received initial approval for obesity treatment, while elsewhere it remains experimental.
Mazdutide is a dual agonist of GLP‑1 and glucagon receptors (GCGR), distinguishing it from both classical GLP‑1 agonists and dual GIP/GLP‑1 agonists. GLP‑1 activation reduces appetite, slows gastric emptying, and improves glycemic control, while glucagon receptor stimulation increases energy expenditure, fatty acid oxidation, and reduces visceral and hepatic fat. This dual mechanism gives mazdutide strong potential for weight reduction and metabolic improvement, with a safety profile characteristic of incretin therapies that is still being evaluated outside China.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 3 mg for the 1st month, 6 mg for the 2nd month, 9 mg for the following months |
|---|---|
| Frequency | every week |
| Time of day | freely |
| Cycle on | to obtain a therapeutic effect — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | - |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
AOD9604
AOD9604 is an experimental compound that underwent clinical investigation but was never approved as a medicinal product. It was developed mainly for obesity treatment, but clinical programs were discontinued, and AOD9604 is not approved for clinical use in any country.
AOD9604 is a synthetic peptide derived from human growth hormone (hGH), designed to selectively influence fat metabolism without activating classical growth hormone receptors. Its mechanism involves stimulating lipolysis and inhibiting lipogenesis, without affecting growth, IGF‑1 levels, or glucose metabolism. Despite promising theoretical assumptions and early study results, AOD9604 did not demonstrate sufficient clinical efficacy to meet regulatory requirements. It is now considered a historical and research compound, not a medical therapy.
Current medical knowledge allows speculation that AOD9604 could theoretically play a supportive role alongside GLP‑1 therapies, complementing them through peripheral lipolysis stimulation. Due to economic considerations, such research is not currently pursued.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 300 mcg |
|---|---|
| Frequency | every day |
| Time of day | in the morning, on an empty stomach |
| Cycle on | 8–12 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | 4 weeks |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
HGH Fragment 176‑191
HGH Fragment 176‑191 is a natural C‑terminal fragment of human growth hormone (hGH) studied for its role in fat metabolism regulation. It has not been approved as a medication, and no medicinal products containing it exist.
This fragment is responsible for the lipolytic effects of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without significantly affecting the GH–IGF‑1 axis or carbohydrate metabolism. Its mechanism is purely peripheral, with no effect on appetite regulation or the central nervous system, meaning it does not produce clinically significant weight loss as monotherapy. As a result, HGH Fragment 176‑191 is now regarded as a conceptual and historical compound, contributing to the development of later molecules such as AOD9604.
Similarly to AOD9604, it is theorized that HGH Fragment 176‑191 could have played a supportive role alongside GLP‑1 therapies, but economic factors have prevented further research.
| The dosing description is not a therapeutic recommendation. The information presented is based on averaged data from multiple sources. | |
| Dose | 250–500 mcg |
|---|---|
| Frequency | 1–2× a day |
| Time of day | morning / pre‑workout |
| Cycle on | 8–12 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. |
| Cycle off | 4 weeks |
CagriSema | Dulaglutide | Liraglutide | Mazdutide | Semaglutide | Tirzepatide | AOD9604 | HGH Fragment 176-191
Worth knowing
The production of peptide medications is costly primarily due to the complexity of synthesis and quality control. After synthesis, extensive purification is required to remove incomplete or incorrect sequences. Manufacturing must take place under GMP pharmaceutical conditions, with rigorous quality control including mass spectrometry and chromatographic analysis of each batch. Peptides are also chemically unstable and prone to degradation, increasing requirements for storage, formulation, and packaging.
Producing the same chemical substance can involve vastly different costs depending on whether it is sold as a medicinal product or as a research chemical. Laboratory reagents are subject to less stringent requirements, allow higher impurity levels, and require less documentation. Pharmaceutical production, by contrast, demands full batch reproducibility, sterility control (where required), pharmaceutical‑grade packaging, and compliance with regulatory transport and storage standards.
As a result, even when the chemical structure is identical, pharmaceutical‑grade production is far more complex and expensive than producing superficially similar research‑grade compounds. Manufacturers of “research chemicals,” even of the highest quality, cannot offer guarantees comparable to pharmaceutical companies, as they are not legally drug manufacturers.
PEPTIDE SUPPLIERS FOR SCIENTIFIC RESEARCH
Many peptides discussed in biohacking or longevity communities are experimental compounds that have not undergone full regulatory evaluation by agencies such as the FDA or EMA. Publicly available information may come primarily from preclinical studies, early‑phase trials, or experimental reports. Consequently, both safety and efficacy profiles may remain uncertain.
This website does not promote the use of unapproved substances, and the information provided does not constitute medical advice. All content is presented solely for educational and informational purposes.